NVIDIA-backed SimBioSys wins FDA clearance for AI tool predicting breast cancer recurrence at 5 and 10 years
nvidia · x · 2026-10-27
- SimBioSys's TumorSight Risk, powered by NVIDIA technology, has received FDA clearance. It analyzes an existing breast MRI alongside pathology and clinical data to estimate breast cancer recurrence risk at 5 and 10 years.
- For HR-positive, HER2-negative early-stage patients, risk insights are available before surgery, giving patients and doctors more information when weighing treatment options.
- The sample report shows a 0-100 TSR Score (a 41 means High risk: 7.4% 5-year and 21.1% 10-year recurrence risk), backed by a clinical validation study of 2,239 patients (High-risk group observed 9.8% recurrence at 5 years).
- SimBioSys CTO Joseph Peterson credits NVIDIA's AI/GPU stack for turning traditional images into real-time, clinically meaningful 3D intelligence used in TumorSight Viz.
More from Apps
- Vibe-coding a better Matter smart home setup in 10 minutes after iPhone Home app timeouts — blixt · 2026-10-27
- Riverside launches 4 AI agents to replace your entire video production crew — SucceededMind · 2026-10-27
- Stripe's PartyDAO Unveils Link Balance, an Internet-Native Payment Method Built for AI Agents — jeff_weinstein · 2026-10-27
- Tomo Community launches: crowdsourced recommendations weighted by preference overlap — Jackyhuang · 2026-10-27
- Stripe exec reveals @link balance stack: Privy wallets, Tempo stablecoins, Stripe onramp — jeff_weinstein · 2026-10-27
- A cozy multiplayer city builder made on Sojo that anyone can co-build — jaivinwylde · 2026-10-27